Olvi-Vec

BIOLOGICAL2 trials

Sponsors

Genelux Corporation, Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

Conditions

Fallopian Tube CancerOvarian CancerPeritoneal CarcinomatosisSCLC, Extensive Stage

Phase 1

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

CompletedNCT02759588

Genelux CorporationFallopian Tube Cancer, Ovarian Cancer, Peritoneal Carcinomatosis

Start: 2016-05-01End: 2022-12-31Updated: 2026-06-12

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

RecruitingNCT07136285

Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.SCLC, Extensive Stage

Start: 2023-07-24End: 2026-12-31Target: 27Updated: 2025-12-03

Related Papers

Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

JAMA Oncology2023-05-2530 citations

12 Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant/refractory ovarian cancer

2020-11-015 citations

120 Factors associated with extended survival for patients with platinum-resistant ovarian cancer (PROC) treated with modified vaccinia oncolytic virotherapy (VOV)

2019-09-01

Factors associated with extended survival for patients with platinum-resistant ovarian cancer treated with modified vaccinia oncolytic virotherapy.

Journal of Clinical Oncology2019-05-20

Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer (ROC).

Journal of Clinical Oncology2018-05-2011 citations